Papers/PMID:41096556
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
International journal of molecular sciences2025The record
8 findings drawn from this paper, on 1 compound across 8 endpoints, 1 of them null.
What it reported
How to read these marksWhat moved
7 findings
curcumin — increases superoxide dismutase activity
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×1“Compared to the placebo group, curcumin supplementation significantly enhanced antioxidant defenses, as evidenced by increased levels of total antioxidant capacity (TAC), glutathione peroxidase (GPx), and superoxide dismutase (SOD) activity at 3, 6, 9, and 12 months.”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Oral ethanolic Curcuma longa rhizome extract standardised to 75-85% total curcuminoids, 250 mg curcuminoids per capsule, three capsules twice daily (1500 mg curcuminoids/day) for 12 months
- Population
- Obese adults with type 2 diabetes mellitus managed on metformin (age >=35 y, BMI >=23 kg/m2, HbA1c <6.5%), Nakhon Nayok, Thailand; 227 randomised, per-protocol analysis and the analysed count is not reported in the paper; secondary endpoint (declared primary outcome: liver steatosis by controlled attenuation parameter on transient elastography); SOD by RANSOD colorimetric assay
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry funded
curcumin — decreases malondialdehyde (circulating)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×4“In parallel, curcumin treatment led to a significant reduction in malondialdehyde (MDA) levels—a key biomarker of oxidative stress—across the same time points (Table 3).”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Dose
- 1500 mg/day curcuminoid extract
- Population
- obese adults with type 2 diabetes mellitus, secondary endpoint
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry funded
curcumin — decreases body mass index
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×2“Anthropometric measurements, including BMI and WC, were significantly lower in the curcumin group compared to the placebo group at 3, 6, 9, and 12 months ( Table 4; B).”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Oral ethanolic Curcuma longa rhizome extract standardised to 75-85% total curcuminoids, 250 mg curcuminoids per capsule, three capsules twice daily (1500 mg curcuminoids/day) for 12 months
- Population
- Obese adults with type 2 diabetes mellitus managed on metformin (age >=35 y, BMI >=23 kg/m2, HbA1c <6.5%), Nakhon Nayok, Thailand; 227 randomised, per-protocol analysis and the analysed count is not reported in the paper; this outcome is named in neither the declared primary nor the declared secondary endpoint list (declared primary outcome: liver steatosis by controlled attenuation parameter); BMI by bioelectrical impedance analyser (Omron HBF-362)
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry funded
curcumin — decreases total cholesterol (TC)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×2“Curcumin supplementation resulted in a significant reduction in total cholesterol and LDL-C levels when compared to the placebo group at the 6, 9, and 12-month time points.”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Oral ethanolic Curcuma longa rhizome extract standardised to 75-85% total curcuminoids, 250 mg curcuminoids per capsule, three capsules twice daily (1500 mg curcuminoids/day) for 12 months
- Population
- Obese adults with type 2 diabetes mellitus managed on metformin (age >=35 y, BMI >=23 kg/m2, HbA1c <6.5%), Nakhon Nayok, Thailand; 227 randomised, per-protocol analysis and the analysed count is not reported in the paper; secondary endpoint (declared primary outcome: liver steatosis by controlled attenuation parameter on transient elastography)
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry funded
curcumin — increases glutathione peroxidase activity
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“Compared to the placebo group, curcumin supplementation significantly enhanced antioxidant defenses, as evidenced by increased levels of total antioxidant capacity (TAC), glutathione peroxidase (GPx), and superoxide dismutase (SOD) activity at 3, 6, 9, and 12 months.”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Oral ethanolic Curcuma longa rhizome extract standardised to 75-85% total curcuminoids, 250 mg curcuminoids per capsule, three capsules twice daily (1500 mg curcuminoids/day) for 12 months
- Population
- Obese adults with type 2 diabetes mellitus managed on metformin (age >=35 y, BMI >=23 kg/m2, HbA1c <6.5%), Nakhon Nayok, Thailand; 227 randomised, per-protocol analysis and the analysed count is not reported in the paper; secondary endpoint (declared primary outcome: liver steatosis by controlled attenuation parameter on transient elastography); GPx by RANSEL colorimetric assay
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry funded
curcumin — increases total antioxidant capacity
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×2“Compared to the placebo group, curcumin supplementation significantly enhanced antioxidant defenses, as evidenced by increased levels of total antioxidant capacity (TAC), glutathione peroxidase (GPx), and superoxide dismutase (SOD) activity at 3, 6, 9, and 12 months.”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Oral ethanolic Curcuma longa rhizome extract standardised to 75-85% total curcuminoids, 250 mg curcuminoids per capsule, three capsules twice daily (1500 mg curcuminoids/day) for 12 months
- Population
- Obese adults with type 2 diabetes mellitus managed on metformin (age >=35 y, BMI >=23 kg/m2, HbA1c <6.5%), Nakhon Nayok, Thailand; 227 randomised, per-protocol analysis and the analysed count is not reported in the paper; secondary endpoint (declared primary outcome: liver steatosis by controlled attenuation parameter on transient elastography); total antioxidant capacity by the automated Erel assay
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry funded
Show the remaining 1
curcumin — decreases tumour necrosis factor alpha concentration
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.Findingreplicated ×1“Curcumin significantly reduced the pro-inflammatory biomarkers IL-1β and TNF-α, (Table 3).”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Dose
- 1500 mg/day curcuminoid extract
- Population
- obese adults with type 2 diabetes mellitus, secondary endpoint
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry funded
What did not
1 finding
curcumin — no detected effect on serum creatinine concentration
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result“A comparison of aspartate transaminase, alanine transaminase, and creatinine levels revealed no significant differences between the curcumin and placebo groups.”
Quoted verbatim from Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.. - Study
- RCT
- Dose
- Oral ethanolic Curcuma longa rhizome extract standardised to 75-85% total curcuminoids, 250 mg curcuminoids per capsule, three capsules twice daily (1500 mg curcuminoids/day) for 12 months
- Population
- Obese adults with type 2 diabetes mellitus managed on metformin (age >=35 y, BMI >=23 kg/m2, HbA1c <6.5%), Nakhon Nayok, Thailand; 227 randomised, per-protocol analysis and the analysed count is not reported in the paper; prespecified safety/adverse-effect assessment, not an efficacy endpoint (declared primary outcome: liver steatosis by controlled attenuation parameter)
Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.2025PMID:41096556Industry funded